logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
P

Peiguo Cao

Central South University
H指数:25
被引数:2,993

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-249.

[1] Sung H, Ferlay J, Siegel RL, 等. 全球癌症统计数据2020：185个国家36种癌症的全球发病率与死亡率GLOBOCAN估算. CA Cancer J Clin 2021;71:209-249.

JHEP REPORTS
IF7.5
2025-02-010
PRE
Finn, Richard S.; Gu, Kangsheng; Chen, Xi; Merle, Philippe; Lee, Kyung-Hun; Bouattour, Mohamed; Cao, Peiguo; Wang, Wei; Cheng, Ann-Lii; Zhu, Liangjun; Lim, Ho Yeong; Kudo, Masatoshi; Pan, Yueyin; Chang, Ting-Tsung; Edeline, Julien; Li, Wei; Yang, Ping; Li, Chen; Li, Jianfeng; Siegel, Abby B.; Qin, Shukui
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase II study

抗EGFR单克隆抗体SCT200在氟尿嘧啶，伊立替康和奥沙利铂难治性RAS和BRAF野生型转移性结直肠癌患者中的疗效，安全性和基因组分析: II期研究

EBIOMEDICINE
IF10.8
2024-02-010
OAAI
Yang, Lin; Zhang, Wen; Fan, Nanfeng; Cao, Peiguo; Cheng, Ying; Zhu, Lingjun; Luo, Suxia; Zong, Hong; Bai, Yuxian; Zhou, Jianfeng; Deng, Yanhong; Ba, Yi; Liu, Tianshu; Aili, Mayinuer; Yin, Xianli; Gu, Kangsheng; Dai, Guanghai; Ying, Jieer; Shi, Jianhua; Gao, Yajie; Li, Wei; Yu, Guohua; Xie, Liangzhi; Gai, Wenlin; Wang, Yan; Meng, Peng; Shi, Yuankai
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
LANCET RESPIRATORY MEDICINE
IF32.8
2023-10-0123
PRE
Lu, Shun; Zhou, Jianying; Jian, Hong; Wu, Lin; Cheng, Ying; Fan, Yun; Fang, Jian; Chen, Gongyan; Zhang, Zhihong; Lv, Dongqing; Jiang, Liyan; Wu, Rong; Jin, Xiangming; Zhang, Xiaodong; Zhang, Junhong; Xie, Conghua; Sun, Gengyun; Huang, Dongning; Cui, Jiuwei; Guo, Renhua; Han, Zhigang; Chen, Zhendong; Liang, Jin; Zhuang, Wu; Hu, Xingsheng; Zang, Aimin; Zhang, Yi; Cang, Shundong; Lan, Yuanbo; Chen, Xi; Liu, Laiyu; Li, Xingya; Chen, Jun; Ma, Rui; Guo, Yanzhen; Sun, Ping; Tian, Panwen; Pan, Yueyin; Liu, Zhe; Cao, Peiguo; Ding, Lieming; Wang, Yang; Yuan, Xiaobin; Wu, Pengxiang
A web-based nomogram model for predicting the overall survival of hepatocellular carcinoma patients with external beam radiation therapy: A population study based on SEER database and a Chinese cohort

基于网络的诺模图模型预测外照射治疗的肝细胞癌患者的总生存期: 基于SEER数据库和中国队列的人群研究

FRONTIERS IN ENDOCRINOLOGY
IF4.6
2023-01-317
OAAI
Zhan, Gouling; Peng, Honghua; Zhou, Lehong; Jin, Long; Xie, Xueyi; He, Yu; Wang, Xuan; Du, Zhangyan; Cao, Peiguo
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial
MOLECULAR CANCER
IF33.9
2022-01-0333
OAAI
Jiang, Tao; Chen, Jianhua; Xu, Xingxiang; Cheng, Ying; Chen, Gongyan; Pan, Yueyin; Fang, Yong; Wang, Qiming; Huang, Yunchao; Yao, Wenxiu; Wang, Rui; Li, Xingya; Zhang, Wei; Zhang, Yanjun; Hu, Sheng; Guo, Renhua; Shi, Jianhua; Wang, Zhiwu; Cao, Peiguo; Wang, Donglin; Fang, Jian; Luo, Hui; Geng, Yi; Xing, Chunyan; Lv, Dongqing; Zhang, Yiping; Yu, Junyan; Cang, Shundong; Zhang, Yaxi; Zhang, Jiao; Yang, Zeyu; Shi, Wei; Zou, Jianjun; Zhou, Caicun; Ren, Shengxiang
Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination vs. Either Agent Alone as Second-Line Treatment for Advanced/Metastatic NSCLC With Wild-Type or Unknown EGFR Status: An Open-Label, Randomized Controlled, Prospective, Multi-Center Phase III Trial (Cando-L1)

多西他赛和斑蝥酸钠联合用药与单独用药作为具有野生型或未知EGFR状态的晚期/转移性NSCLC二线治疗的疗效和安全性: 一项开放标签，随机对照，前瞻性，多中心III期试验 (Cando-L1)

FRONTIERS IN ONCOLOGY
IF3.3
2021-12-142
OAAI
Wu, Lin; Deng, Chao; Zhang, Hui; Weng, Jie; Wu, Youhua; Zeng, Shan; Tang, Tiegang; Cao, Peiguo; Qiu, Bo; Zhang, Li; Duan, Huaxin; Zhang, Bing; Zhang, Dong; Zhang, Taotao; Hu, Chunhong

研究方向

暂未获取到该数据
J
Jianda Zhou
H 指数:32论文数:134被引数:4,055
K
Ke Cao
H 指数:42论文数:251被引数:7,658
K
Ke Cao
H 指数:13论文数:26被引数:757
S
Shukui Qin
H 指数:76论文数:578被引数:5.1万
C
Chenghui Huang
H 指数:14论文数:49被引数:751
J
Jianfeng Zhou
H 指数:19论文数:85被引数:1,455
程
程颖
H 指数:84论文数:1,042被引数:4.4万
H
Haijun Zhong
H 指数:19论文数:119被引数:2,789
Y
Yuxian Bai
H 指数:59论文数:366被引数:1.9万
Y
Yuliang Pan
H 指数:12论文数:32被引数:536